What's breaking now, across thousands of outlets.
Cheaper weight-loss drugs were expected to take off in India. But despite GLP-1s costing as little as $14 a month, demand has been slower than expected. From stigma to hesitant doctors, Satviki Sanjay explains why price isn’t the only barrier. (Source: Bloomberg)
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
Trump’s push to acquire Greenland and growing uncertainty over U.S. security commitments have added a geopolitical dimension to Iceland’s EU debate.
A sprawling London fresh produce market is producing its own power thanks to record-breaking rooftop solar.
(RTTNews) - Rivian Automotive, Inc. (RIVN), an automotive technology company, Thursday announced that its Chief Financial Officer, Claire McDonough is stepping down, effective October 30, to pursue a…
The USD/CAD pair trades on a flat note around 1.3850 during the early European trading hours on Friday. Traders prefer to wait on the sidelines ahead of Federal Reserve (Fed) Chair Kevin Warsh's…
The stock began trading at ₹631.20 on the BSE and ₹634.00 on the NSE, more than doubling from its offer price of ₹300
Citi Pharma Limited is seeking shareholder approval to expand its business into cannabis, industrial hemp, and medicinal cannabis activities in … Read More The post Citi Pharma Eyes Cannabis and Hemp…
